How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

CY

NASDAQ:CYTO
Get a brief AI stock analysisSaves ~ 15 minutes of your time

CY

Altamira Therapeutics LtdNASDAQ CYTO Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is CYTO undervalued compared to its fair value?

The fair value of CYTO stock is hidden USD. Relative to the market price of 1.08 USD Altamira Therapeutics Ltd is hidden.

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The company is engaged in developing therapeutics that addresses...[More about valuation]

Altamira Therapeutics Fair Value

Available for registered user
UNLOCK
What is fair value?

Market cap:

0.002 $B

Price:

1.08 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-7.876

FINANCIALS

Altamira Therapeutics financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0059 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0039 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.0077 B
0.0065 B

Financial Position Analysis

Assets

0.0077 B
Current Assets
0.0012 B
Total non-current assets
0.0065 B

Total current liabilities
0.0009 B
Total non-current liabilities
0.0003 B

Cash Flow Statement

-N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0038 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Altamira Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-401 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-230 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-134 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Altamira Rating

Is CYTO attractive for investment based on fundamental analysis?

CYTO stock rating is hidden. Altamira Therapeutics is a hidden by Eyestock methodology.

Get CYTO Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-8 808

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

0.472

Debt / Equity ratio:

0.661

ROE:

-401

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

CYTO analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for CYTO to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Altamira Therapeutics Ltd dividends

CYTO dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About CYTO stock

About the company Altamira Therapeutics Ltd

Market cap $B

0.002

Dividend yield

Shares outstanding

1.16921 B

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The company is engaged in developing therapeutics that addresses unmet medical needs. The firm is active in three areas, namely the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore/SemaPhore platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio; commercial) or for the treatment of vertigo (AM-125; Phase II), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen and Sonsuvi; Phase III). Its nanoparticle delivery platform OligoPhore and its equivalent SemaPhore engages any type of short interfering RNA (siRNA) or messenger RNA (mRNA), respectively, in rapid self-assembly. Its platform enables delivery to target tissues outside the liver, creating the potential for developing RNA-based therapies for a range of indications.

CYTO profile

  • Ticker

    CYTO

  • Country

    Bermuda

  • Exchange

    XNAS - Nasdaq

  • Report currency

    CHF - Swiss franc

  • IPO date

    06 August 2014

  • Sector

    Healthсare

  • Industry

    Pharmaceuticals

  • Employees

    17

  • City

    Hamilton

  • Address

    Clarendon House, 2 Church Street

  • Cusip

    G0360L209

Frequently Asked Questions

What sector does Altamira operate in?

Altamira operates in Healthсare sector

What is market cap of Altamira?

Market cap of Altamira is 0.002 USD as of 23 Jul 2024

What is market price of one CYTO stock?

Market price of one CYTO stock is 1.08 USD as of 23 Jul 2024

What is Altamira revenue?

According to the recent report Altamira revenue is —

What is Altamira net income?

According to the recent report Altamira net icnome is -3.86917

What is Altamira net income growh rate?

Net income growth rate of Altamira is 73